Eicosapentaenoic acid shows limited benefitsHigher epicardial adipose tissue volume is associated with higher coronary fatty plaque volume and is regulated by waist circumference but not EPA+DHA supplementation.
Most Relevant Research
We conducted a study to see how eicosapentaenoic acid (EPA) impacts epicardial adipose tissue volume (EATV) and its relationship with arteriosclerosis in individuals with coronary artery disease (CAD). The research involved 139 subjects already on statins, who were either given a daily dose of 3.36 grams of EPA and docosahexaenoic acid (DHA) or received no supplement for 30 months.
Our findings revealed that although EPA+DHA supplementation resulted in a notable reduction in triglyceride levels, there was no significant decrease in EATV when compared to those who did not receive the supplement. Interestingly, we observed that waist circumference was the primary factor influencing EATV levels, suggesting that managing weight might be more crucial than supplementation for reducing heart-related issues.
Furthermore, we found that individuals with higher EATV measurements tended to have more coronary fatty plaque. This highlights the connection between body weight and cardiovascular health, as having a larger waist circumference predicted an increase in EATV after 30 months. In conclusion, while EPA+DHA can lower triglycerides, it didn’t directly affect EATV in our study, underscoring the importance of maintaining a healthy weight to potentially reduce the risk of arteriosclerosis and associated heart events.